Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Oct 14 (Reuters) — Rezolute, Inc.: Rezolute Announces Completion Of Enrollment In Phase 3 Uplift Study Of Ersodetug In Tumor Hyperinsulinism Rezolute - Completes Enrollment In Phase 3 Uplift Study; Topline Results Expected Mid-december 2026 Rezolute - Primary Endpoint Is 50% Reduction In Glucose Infusion Rate Within 8
Rezolute says enrollment is complete in the Phase 3 Uplift study of ersodetug in tumor hyperinsulinism.
Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism. Topline results are expected in mid-December 2026. * Previously reported results showed seven of the first eight participants met the primary endpoint; all seven stopped intravenous glucose treatment. No
Rezolute said topline results from its upLIFT study in tumor hyperinsulinism are expected in mid-December 2026.
Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism.